期刊
JOURNAL OF MATERIALS CHEMISTRY B
卷 9, 期 1, 页码 23-34出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0tb02094j
关键词
-
资金
- National Key Research and Development Program of China [2019YFA0111300]
- Guangdong Province Science and Technology Innovation Special Fund (International Scientific Cooperation) [2018A050506035]
- National Natural Science Foundation of China [51903256, 21907113, 81670688, 81800666]
- Guangdong Province Natural Science Foundation of China [2016A030313192, 2017A030310414, 2018A0303130330]
- Fundamental Research Funds for the Central Universities [19ykpy33]
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and painful bladder condition with challenging treatment outcomes. Current administration routes, such as intravesical-bladder injection, have improved efficacy but face hindrances due to the bladder permeability barrier.
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and painful bladder condition afflicting patients with increased urinary urgency and frequency as well as incontinence. Owing to the elusive pathogenesis of IC/BPS, obtaining effective therapeutic outcomes remains challenging. Current administrational routes such as intravesical-bladder injection improve the treatment efficacy and reduce systemic side effects. However, the bladder permeability barrier hinders drug penetration into the bladder wall to meet the desired therapeutic expectation. These issues can be addressed by encapsulating drugs into biomaterials. When appropriately exploited, they would increase the drug dwelling time in the bladder, enhance the penetration of mucosa and improve the therapeutic response of IC/BPS. In this review, we first elucidate the pathogenesis and animal models of IC/BPS. Then, we highlight recent representative biomaterial-assisted drug delivery systems for IC/BPS treatment. Finally, we discuss the challenges and outlook for further developing biomaterial-based delivery systems for IC/BPS management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据